Q4 Sales Growth (Currency-Adjusted)
Net sales of SEK 2.272 billion in Q4, representing approximately 2% growth adjusted for currency headwinds (company-stated).
Full-Year Sales and Profitability Improvement
Full-year 2025 sales close to SEK 9.5 billion, +2% adjusted for currency. Operating profit increased 11% for the year and EBITA margin improved to 11.3% from 9.9% (increase of 1.4 percentage points).
Earnings Per Share and Dividend
Earnings per share of SEK 2.88 for 2025. Dividend proposal increased to SEK 1.70 per share from SEK 1.50, with a payout ratio of 59% (down from 61%).
Medical Solutions Growth and Scale
Medical Solutions delivered just above SEK 1.3 billion in Q4 sales, +5% adjusted for currency, and now represents 58% of group sales. Medical margin at 11.6% (up 0.4 percentage points vs 2024). Ongoing expansions in Hungary, Poland and Malaysia support global growth.
Engineered Solutions — Materials Performance
Engineered Solutions sales near SEK 1 billion in Q4 (42% of group sales). Materials subsegment grew ~10% adjusted for currency, and the Engineered business area margin improved to 9.9% from 9.2%.
Strong Cash Generation and Capital Discipline
Operating cash flow of SEK 310 million in the quarter. Q4 CapEx was SEK 146 million; full-year 2026 CapEx guidance set at SEK 650–700 million (around SEK 100 million remaining for the Hungarian project).
Return on Capital Employed
Return on capital employed (ROCE) improved to 14.2% for the full year 2025, indicating stronger capital efficiency.
Sustainability Milestones
Scope 1 & 2 emissions reduced by 96% vs base year (2021) — well ahead of the 70% 2030 target. Scope 3 upstream emissions reduced by 30% vs base year (vs 25% target). Net-zero 2045 target approved by SBTi.